Rapid Lipid Modification of Endothelial Cell Membranes in Cardiac Ischemia/Reperfusion Injury: a Novel Therapeutic Strategy to Reduce Infarct Size.
Claudio MaldonadoMai-Dung NguyenPhillip BauerShunichi NakamuraSyed J KhundmiriGustavo Perez-AbadiaHeather L StowersWen-Jian WuXian-Liang TangPublished in: Cardiovascular drugs and therapy (2020)
The IC FNL-MLT reduced IS (25.45 ± 16.4% vs. 49.7 ± 14.1%, P < 0.02) and enhanced regional myocardial blood flow (RMBF) in the ischemic zone at 15 min of reperfusion (2.13 ± 1.48 mL/min/g vs. 0.70 ± 0.43 mL/min/g, P < 0.001). The total cumulative plasma levels of the cardiac injury biomarker cardiac troponin I (cTnI) were trending downward but were not significant (999.3 ± 38.7 ng/mL vs. 1456.5 ± 64.8 ng/mL, P = 0.1867). However, plasma levels of heart-specific fatty acid binding protein (hFABP), another injury biomarker, were reduced at 2 h of reperfusion (70.3 ± 38.0 ng/mL vs. 137.3 ± 58.2 ng/mL, P = 0.0115). CONCLUSION: The IC FNL-MLT reduced IS compared to vehicle in this swine model. The FNL-MLT maybe a promising adjuvant to PCI in the treatment of acute MI.
Keyphrases
- acute myocardial infarction
- blood flow
- ischemia reperfusion injury
- left ventricular
- fatty acid
- cerebral ischemia
- binding protein
- endothelial cells
- coronary artery disease
- percutaneous coronary intervention
- acute coronary syndrome
- early stage
- liver failure
- st segment elevation myocardial infarction
- blood brain barrier
- subarachnoid hemorrhage
- intensive care unit
- antiplatelet therapy
- quantum dots